GSK-3β inhibitor 28 is a selective, non-competitive inhibitor of glycogen synthase kinase-3β (GSK-3β), with an IC50 value of 14.82 nM. It enhances the expression of phosphorylated GSK-3β while reducing the levels of p-NF-κB, P65, C-myc, and Cyclin D1. This compound induces apoptosis, causes G1 phase arrest, and inhibits cell migration. GSK-3β inhibitor 28 is applicable for cancer research, including studies on colorectal cancer.